| Name | Abarelix |
| Description | Abarelix (PPI 149) is a potent gonadotrophin-releasing hormone (GnRH) antagonist, which is used for prostate cancer treatment. |
| In vitro | Abarelix, at concentrations of 30 and 300 µg/mL, significantly increases histamine release[1]. It rapidly and considerably lowers follicle-stimulating hormone levels below those achieved by LHRH agonists. As the inaugural GnRH antagonist developed, Abarelix achieves fast and sustained testosterone reductions to castrate levels without requiring concurrent antiandrogen therapy, exhibiting a remarkably low short-term complication rate[2]. Unlike other treatments, it avoids the testosterone surge that can exacerbate symptoms or disease progression, particularly in patients with metastatic, symptomatic conditions, facilitating quicker medical castration[3]. |
| Storage | keep away from moisture | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | DMSO : 14.2 mg/mL (10.03 mM), Sonication is recommended.
|
| Keywords | R-3827 | R 3827 | PPI-149 | PPI149 | Inhibitor | inhibit | Gonadotropin releasing hormone receptor | GNRHReceptor | GnRHR | GNRHR | GNRH Receptor | GnRH Receptor | Abarelix |
| Inhibitors Related | Histrelin acetate | Cetrorelix Acetate | Relugolix | Deslorelin acetate(57773-65-6 free base) | Opigolix | Goserelin acetate | Linzagolix choline | LGnRH-III, lamprey acetate(147859-97-0 free base) | Alarelin Acetate | Cetrorelix diacetate | Lecirelin acetate(61012-19-9 free base) | AG 045572 |
| Related Compound Libraries | Bioactive Compound Library | Membrane Protein-targeted Compound Library | Anti-Cancer Clinical Compound Library | Drug Repurposing Compound Library | Peptide Compound Library | Inhibitor Library | FDA-Approved Drug Library | Anti-Cancer Approved Drug Library | Bioactive Compounds Library Max | GPCR Compound Library | Anti-Cancer Drug Library | Anti-Cancer Active Compound Library |